# US 6,730,657 B1 · Recombinant proteins from HGF and MSP

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,657 B1
- Document ID: US6730657B1
- Status: Granted
- Kind: B1
- Application number: 09/601,040
- Filed: 2000-09-08
- Granted: 2004-05-04
- Earliest claimed: 1998-01-30
- Assignees: Dompe S.p.A.
- Inventors: Enzo Medico; Paolo Michieli; Chiara Colessi; Gianfranco Caselli; Paolo Comoglio
- Web page: https://patentgrep.com/patent/US6730657B1

## CPC

- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/02: containing a signal sequence
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Recombinant proteins derived by recombination of structural domains obtained from alpha and beta subunits of HGF and/or MSP growth factors. These recombinant proteins contain domains selected from HGF and MSP, and are useful to protect cells, including differentiated cell elements of liver, kidney, and mucosa of the gastorenteral tract, from death (i.e., apoptosis) induced by chemotherapeutics.

## Claims

### Claim 1

A recombinant protein of the formula:
LSHGF—HLHGF—K1HGF—K2HGF—K3HGF—K4HGF—BHGF—CβMSP—D
wherein
LSHGF—HLHGF—K1HGF—K2HGF—K3HGF—K4HGF is the sequence comprising amino acids 1-487 of HGF (SEQ ID NO:27),
BHGF is the sequence LLRVV (SEQ ID NO:26),
CβMSP is the sequence 486-711 of MSP (SEQ ID NO:28), and
D is the sequence GNSAVD(H)6 (SEQ ID NO: 13).

### Claim 2

A recombinant protein of formula:
LSHGF—HLHGF—K1HGF—K2HGF—K3HGF—K4HGF—BF—CβMSP—D
wherein
LSHGF—HLHGF—K1HGF—K2HGF—K3HGF—K4HGF is the sequence 1-487 of HGF SEQ ID NO:27),
BF is the sequence RTKR-LRVV (SEQ ID NO: 15),
CβMSP is the sequence 486-711 of MSP (SEQ ID NO:28), and
D is the sequence GNSAVD(H)6 (SEQ ID NO:13).

### Claim 3 (depends on 1, 2)

A method for the treatment of chemotherapeutic-induced toxicity which comprises administering to a patient who has or is to be exposed to chemotherapeutic-induced toxicity a pharmaceutical composition that contains an effective amount of the recombinant protein of claim 1 or claim 2, together with a pharmacologically acceptable exipient.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the chemotherapeutic-induced toxicity is myelotoxicity, hepatotoxicity, nefrotoxicity, mucotoxicity, or neurotoxicity.

### Claim 5 (depends on 1, 2)

A pharmaceutical composition containing an effective amount of the recombinant protein of claim 1 or claim 2, together with a pharmacologically acceptable excipient.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the chemotherapeutic-induced toxicity is apoptosis on differentiated cell elements of liver, kidney, and mucosa of the gastroenteral tract.
